In partnership with Emory University School of Medicine, Children's Carlos and Marguerite Mason Transplant Center is dedicated to finding answers that can make a difference in the lives of children with kidney disease. Our researchers participate in advanced clinical research for kidney transplants, giving children better options for transplants and innovative therapies.
We are involved in:
- Chronic Kidney Disease in Children (CKiD): A study of the effects of chronic kidney disease on children, sponsored by the National Institutes of Health (NIH).
- Clinical Trials in Organ Transplantation in Children (CTOT-C): A cooperative research program, sponsored by the National Institute of Allergy and Infectious Diseases, that conducts clinical studies that will lead to improved outcomes for children who’ve received transplants.
- Nephrotic Syndrome Study Network (NEPTUNE): A study of children with nephrotic syndrome, a group of symptoms that indicate kidney damage and result in the release of too much protein from the body into the urine. Researchers are seeking to understand the cause and find better treatments.
Other areas our researchers are investigating include:
- Adolescent transplant patients’ adherence to their medication and lifestyle regimen, and transitioning them from pediatric- to adult-centered care
- Behavioral consequences of solid organ transplant
- Cystinosis, an inherited disease that causes the amino acid cysteine to accumulate in cells and form crystals that can damage organs and lead to kidney failure
- Effects of chronic kidney disease in children
- High blood pressure
- Strategies to prevent the immune response (immunosuppressive strategies)
- Nephrotic syndrome and focal segmental glomerulosclerosis (FSGS), a cause of nephrotic syndrome in children and adolescents
- New medications to prevent transplant rejection
- Noninvasive strategies to monitor kidney transplant recipients
Children's is also at the forefront of research for atypical hemolytic-uremic syndrome, a disease that primarily affects kidney function. Our doctors performed a kidney transplant combined with an experimental drug therapy to treat the condition—only the third patient in the U.S. to receive this type of treatment.